Efficacy and safety of cholesterol-lowering treatment [3]

Lancet

Volumn 367, Issue 9509, 2006, Pages 469-470

  Law, Malcolm ^a   Wald, Nicholas J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIORITY JOURNAL; PUBLICATION; RISK REDUCTION; TREATMENT DURATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HYPERLIPIDEMIA; MALE; NOTE; WOMEN'S HEALTH; BLOOD; DOSE RESPONSE; HYPERCHOLESTEROLEMIA; TIME;

CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; WOMEN'S HEALTH; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERCHOLESTEROLEMIA; TIME FACTORS;

EID: 32144464555     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68170-1     Document Type: Letter

References (3)

1. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. Law MR, Wald NJ, Rudnicka AR Quantifying the effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review andg meta-analysis BMJ 326 2003 1423 1427
3. Law MR, Wald NJ, Thompson SG By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 307 1994 367 372